Overview
To evaluate effect on comorbid disease and weight loss in the long-term (>five years) after Roux-en-Y gastric bypass (RYGB) surgery for severe obesity.
Description
Individuals with severe obesity frequently have comorbid diseases, e.g. diabetes, hypertension, hyperlipidemia, and sleep apnea. We will study the remission rate and weight loss in the long-term (10 years) after Roux-en-Y gastric bypass (RYGB) surgery in a nationwide large group of patients.
Eligibility
Inclusion Criteria:
- Registered individuals in Scandinavian Obesity Surgery Registry (SOReg) having had gastric bypass
Exclusion Criteria:
- All other operations